8-K: Verrica Pharmaceuticals Secures $18M Non-Dilutive Capital, Accelerates Global Phase 3 Trial for Common Warts

Verrica Pharmaceuticals Inc. announced a second amendment to its collaboration agreement with Torii Pharmaceutical, securing $18 million in non-dilutive milestone payments and advancing a global Phase 3 clinical trial for YCANTH in common warts.

Summary

• Verrica Pharmaceuticals Inc. entered into a second amendment to its Collaboration and License Agreement with Torii Pharmaceutical Co., Ltd. on June 27, 2025.
• Torii will provide an accelerated $8.0 million milestone payment in July 2025 for the initiation of the global Phase 3 clinical trial of YCANTH (VP-102) for common warts.
• Torii will also pay a $10.0 million milestone payment in cash if YCANTH is approved for molluscum contagiosum in Japan, expected by the end of 2025, rather than as an offset to trial costs.
• The total new non-dilutive capital expected in 2025 from these payments is $18 million.
• The Parties will continue to equally split the cost of the global Phase 3 common warts trial, with Torii paying the first $40.0 million of out-of-pocket costs, representing approximately 90% of the current clinical budget.
• Verrica will repay Torii half of the trial costs by offsetting amounts otherwise owed for future royalties, certain transfer price payments, and remaining development milestones.
• If trial costs exceed $40.0 million, Verrica will pay such excess costs up to a specified maximum, with Torii repaying Verrica half of those costs.
• A technology transfer to Torii to enable manufacturing of YCANTH applicators for Japan will begin promptly, with Verrica receiving transfer price payments for commercial supply in the interim.
• After partial manufacturing transfer, Verrica will receive quarterly royalty payments from Torii at a rate ranging from high single digits to low double digits on net sales in Japan.
• Verrica expects to dose the first patient in the global Phase 3 program in the United States in the fourth quarter of 2025.
• Verrica maintains ownership of global rights to YCANTH for all indications in all territories outside of Japan.
• An amendment to Verrica's Credit Agreement with OrbiMed waived the requirement for no going concern qualification to its financial statements for the remainder of 2025.

Sentiment

Score: 8

Explanation: The announcement is overwhelmingly positive, providing significant non-dilutive capital, accelerating a major clinical program into a large unmet market, and improving financial flexibility by waiving a going concern clause. The strategic partnership is strengthened, and the company's outlook appears significantly de-risked for 2025.

Positives

• Secured $18 million in new, non-dilutive capital in 2025, including an accelerated $8 million milestone payment in July 2025.
• Received a commitment for a $10 million cash milestone payment upon Japanese approval of YCANTH for molluscum contagiosum, rather than a cost offset.
• Initiation of a global pivotal Phase 3 clinical trial for YCANTH in common warts, a multi-billion dollar market with approximately 22 million patients in the U.S. and no FDA-approved prescription therapies.
• Torii Pharmaceutical will fund the first $40 million of out-of-pocket costs for the global Phase 3 trial, covering approximately 90% of the current clinical budget.
• Verrica retains global rights to YCANTH for all indications in all territories outside of Japan.
• An amendment to the Credit Agreement with OrbiMed waived the 'going concern' qualification requirement for financial statements for the remainder of 2025, improving financial flexibility.

Negatives

• Verrica is still responsible for repaying Torii half of the first $40 million in trial costs, to be offset against future royalties and other payments.
• Verrica will pay excess trial costs beyond $40 million up to a specified maximum, with Torii repaying half of those excess costs.
• The manufacturing technology transfer to Torii is expected to take several years.

Risks

• Risks and uncertainties related to market conditions.
• Risks and uncertainties related to the satisfaction of customary closing conditions related to the proposed public offering.
• Other risks and uncertainties described in Verrica's Annual Report on Form 10-K for the year ended December 31, 2024, and other filings with the SEC.

Future Outlook

Verrica expects to file the Second Amendment as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending June 30, 2025. The company anticipates receiving an $8 million cash payment from Torii in July 2025 and expects the approval decision for YCANTH for molluscum contagiosum in Japan by the end of 2025. The first patient in the global Phase 3 program for common warts in the United States is expected to be dosed in the fourth quarter of 2025. A manufacturing technology transfer to Torii is planned but is expected to take several years, during which Verrica will continue to receive transfer price payments. Post-transfer, Verrica will receive royalties on Japanese net sales. The company remains focused on driving demand for YCANTH for molluscum contagiosum and plans to provide an update on dispensed applicator unit growth in July.

Management Comments

• Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica, stated: "We are extremely excited to begin our global Phase 3 program in common warts, which has the potential to transform our company by expanding YCANTHs label to one of the most prevalent skin conditions."
• Dr. Rieger commented: "This amendment reflects our extensive collaboration with Torii as we have together worked with regulatory authorities to optimize the clinical program across Japan and the United States, creating strategic, development and financial synergies for both companies."
• Dr. Rieger added: "With no currently FDA approved prescription products available to address the approximately 22 million people in the U.S. impacted by common warts, we believe that expanding YCANTHs label to include this indication would provide millions of patients with a new treatment option in this multi-billion dollar market."
• Dr. Rieger noted: "Verrica is proud to embark on this clinical program with Torii, who continues to be an outstanding and supportive development partner."
• Dr. Rieger also expressed: "We also appreciate the continued support from OrbiMed, our lending partner, who has been of great assistance throughout the restructuring of our company and the implementation of our new commercial strategy for YCANTH."
• Dr. Rieger highlighted: "As a result of our continued execution of our strategy, we recently secured an amendment to our Credit Agreement with OrbiMed whereby the requirement that there be no going concern qualification to our financial statements was waived for the remainder of 2025."
• Dr. Rieger concluded: "As we enter the second half of 2025, the added flexibility and non-dilutive cash resources from the amended agreements with Torii and OrbiMed place us in a far stronger position to continue executing on our YCANTH commercial strategy and moving forward with our label expansion efforts. We remain focused on driving demand for YCANTH as the only FDA approved and commercially available therapy for the treatment of molluscum contagiosum, and we look forward to providing an update on YCANTH dispensed applicator unit growth in July."

Industry Context

The announcement positions Verrica Pharmaceuticals at the forefront of dermatology therapeutics, particularly in addressing significant unmet needs. The focus on common warts, a condition affecting approximately 22 million patients in the U.S. with no current FDA-approved prescription therapies, highlights a substantial multi-billion dollar market opportunity. YCANTH's existing status as the first and only FDA-approved treatment for molluscum contagiosum (affecting 6 million U.S. patients) further solidifies Verrica's leadership in treating prevalent skin conditions requiring medical intervention. The global collaboration with Torii Pharmaceutical underscores a strategic approach to market expansion and clinical development in key regions like Japan.

Comparison to Industry Standards

• The document highlights a significant unmet medical need in the common warts market, stating there are no FDA-approved prescription therapies for this condition affecting approximately 22 million patients in the United States. This positions YCANTH as a potential first-in-class prescription treatment for a multi-billion dollar addressable market, which is a strong competitive advantage.
• For molluscum contagiosum, YCANTH is explicitly stated as the 'first and only commercially available product approved by the FDA,' indicating a leading and unique market position compared to other treatments or non-prescription options.
• The collaboration structure, with Torii funding the majority of initial Phase 3 trial costs and providing non-dilutive milestone payments, is a favorable arrangement that de-risks the development process for Verrica, especially given the large scale of a global pivotal trial.

Corporate Governance

Related Party Transactions

• Amendment to the Collaboration and License Agreement with Torii Pharmaceutical Co., Ltd., a key development and commercialization partner.
• Amendment to the Credit Agreement with OrbiMed, a lending partner, providing financial flexibility.

Stakeholder Impact

• **Shareholders**: Positive impact due to significant non-dilutive capital infusion, advancement of a major clinical program into a large market, improved financial stability through the waiver of a 'going concern' qualification, and retention of global rights outside Japan.
• **Patients**: Potential for a new FDA-approved treatment option for common warts, addressing a significant unmet need, and continued access to the only FDA-approved treatment for molluscum contagiosum.
• **Employees**: Continued focus on commercial strategy and label expansion efforts, potentially leading to increased opportunities as the company advances its pipeline and commercial reach.
• **Torii Pharmaceutical Co., Ltd.**: Strengthened collaboration, shared development costs for a global trial, and initiation of technology transfer to enable manufacturing for the Japanese market.
• **OrbiMed (Lending Partner)**: Continued partnership and support, demonstrated by the amendment to the Credit Agreement, reflecting confidence in Verrica's strategic execution.

Next Steps

• Verrica expects to file the Second Amendment as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending June 30, 2025.
• The Parties shall begin a technology transfer to Torii to enable Torii to manufacture the Product.
• Verrica expects to receive the $8 million cash payment from Torii in July 2025.
• Verrica expects the approval decision for YCANTH (TO-208) for molluscum contagiosum in Japan by the end of 2025.
• Verrica expects to dose the first patient in the global Phase 3 program in the United States in the fourth quarter of 2025.
• Verrica will continue to receive transfer price payments from Torii for commercial supply of the Product prior to the establishment of a partial technology transfer.
• After transfer of a portion of the manufacturing process to Torii, Verrica will begin receiving quarterly royalty payments related to net sales in Japan.
• Verrica looks forward to providing an update on YCANTH dispensed applicator unit growth in July.

Key Dates

Recommendation

Keywords

Verrica Pharmaceuticals, YCANTH, VP-102, Torii Pharmaceutical, Collaboration Agreement, Phase 3 Clinical Trial, Common Warts, Molluscum Contagiosum, Milestone Payment, Dermatology, Clinical Development, FDA Approval, Non-dilutive Capital, OrbiMed, Credit Agreement